drugset / Trial / NCT00937391

Contrast-enhanced MRI in Children 2 Months to <2 Years

NCT00937391

Phase 3 Completed 54 enrolled Bayer
Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

The purpose of this study is to determine pharmacokinetics, safety and efficacy of Magnevist in children 2 months to \< 2 years of age

Timeline

Start
2010-01
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Gadopentetate dimeglumine Diagnostic / imaging agent 0.05 unknown Intravenous
Subject Gadopentetate dimeglumine Diagnostic / imaging agent 0.1 unknown Intravenous

Indications

No indication recorded.